The China-based immuno-oncology company, backed by Merck & Co since 2011, floated at the top of it range and has gained since its debut yesterday.

BeiGene, a China-based biopharmaceutical company that counts pharmaceutical firm Merck & Co among its investors, went public in the US yesterday, floating in a $158.4m initial public offering.

A total of 6.6 million American Depositary Shares, each representing 13 normal shares, were issued, priced at $24.00 each, the top of the $22 to $24 range set by the company.

BeiGene is developing immuno-oncology drugs, and will invest $79m of the proceeds in advancing its drug pipeline through the dose-escalation…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?